Is the 5-port approach necessary in laparoscopic gastrectomy? Comparison of surgical effects of reduced-port laparoscopic gastrectomy and conventional laparoscopic-assisted gastrectomy: A meta-analysis.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
16 Oct 2020
16 Oct 2020
Historique:
entrez:
21
10
2020
pubmed:
22
10
2020
medline:
5
11
2020
Statut:
ppublish
Résumé
Reduced-port surgery, in which fewer ports are used than those in conventional laparoscopic surgery, is becoming increasingly popular for various procedures. However, the application of reduced-port surgery to the gastrectomy field is still underdeveloped. The aim of this study was to use meta-analysis to address the potentially important advantages of this surgical technique. Embase, PubMed, and Cochrane Library databases were systematically reviewed (through October 2019) to identify studies that compared reduced-port (RPLG) and conventional laparoscopic-assisted gastrectomy (CLG) in patients with gastric carcinoma. The endpoints were postoperative time, length of in-hospital stay, blood loss, retrieved lymph nodes, postoperative complications, time to first flatus, and aesthetic outcome. A total of 11 studies, which included 1743 patients (907 RPLG and 836 CLG), were ultimately included in this analysis. Better aesthetic results: were obtained with RPLG (risk ratio 1.578; 95%CI, 1.377-1.808; P = .000), although length of in-hospital stay (standard mean difference [SMD] -0.106; 95% CI, -0.222 to 0.010; P = .074), time to first flatus (SMD -0.006; 95%CI, -0.123 to 0.110; P = .913), and perioperative complications (risk ratio 0.255; 95%CI, 0.142-0.369; P = .478) were equivalent. However, operative time was significantly longer (SMD 0.301; 95%CI, 0.194-0.409; P = .00), blood loss was greater (SMD -0.31; 95%CI, -0.415 to 0.205; P = .000), and fewer lymph nodes were harvested (SMD 0.255; 95%CI, 0.142-0.369; P = .000) in the RPLG group. Our meta-analysis showed that RPLG is as safe as the CLG approach and offers better aesthetic results for patients with gastric carcinoma. However, basing on current evidence, RPLG was not an efficacious surgical alternative to CLG, as operative time was significantly longer, blood loss was greater, and fewer lymph nodes were harvested in the RPLG group. Additional high-powered controlled randomized trials are required, to determine whether RPLG truly offers any advantages; these future studies should particularly focus on pain scores and aesthetic outcomes.
Sections du résumé
BACKGROUND
BACKGROUND
Reduced-port surgery, in which fewer ports are used than those in conventional laparoscopic surgery, is becoming increasingly popular for various procedures. However, the application of reduced-port surgery to the gastrectomy field is still underdeveloped. The aim of this study was to use meta-analysis to address the potentially important advantages of this surgical technique.
METHODS
METHODS
Embase, PubMed, and Cochrane Library databases were systematically reviewed (through October 2019) to identify studies that compared reduced-port (RPLG) and conventional laparoscopic-assisted gastrectomy (CLG) in patients with gastric carcinoma. The endpoints were postoperative time, length of in-hospital stay, blood loss, retrieved lymph nodes, postoperative complications, time to first flatus, and aesthetic outcome.
RESULTS
RESULTS
A total of 11 studies, which included 1743 patients (907 RPLG and 836 CLG), were ultimately included in this analysis. Better aesthetic results: were obtained with RPLG (risk ratio 1.578; 95%CI, 1.377-1.808; P = .000), although length of in-hospital stay (standard mean difference [SMD] -0.106; 95% CI, -0.222 to 0.010; P = .074), time to first flatus (SMD -0.006; 95%CI, -0.123 to 0.110; P = .913), and perioperative complications (risk ratio 0.255; 95%CI, 0.142-0.369; P = .478) were equivalent. However, operative time was significantly longer (SMD 0.301; 95%CI, 0.194-0.409; P = .00), blood loss was greater (SMD -0.31; 95%CI, -0.415 to 0.205; P = .000), and fewer lymph nodes were harvested (SMD 0.255; 95%CI, 0.142-0.369; P = .000) in the RPLG group.
CONCLUSIONS
CONCLUSIONS
Our meta-analysis showed that RPLG is as safe as the CLG approach and offers better aesthetic results for patients with gastric carcinoma. However, basing on current evidence, RPLG was not an efficacious surgical alternative to CLG, as operative time was significantly longer, blood loss was greater, and fewer lymph nodes were harvested in the RPLG group. Additional high-powered controlled randomized trials are required, to determine whether RPLG truly offers any advantages; these future studies should particularly focus on pain scores and aesthetic outcomes.
Identifiants
pubmed: 33080686
doi: 10.1097/MD.0000000000022525
pii: 00005792-202010160-00019
pmc: PMC7571981
doi:
Types de publication
Comparative Study
Journal Article
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Pagination
e22525Références
Surg Endosc. 2016 Aug;30(8):3559-66
pubmed: 26721692
Asian J Endosc Surg. 2014 Aug;7(3):197-205
pubmed: 24767611
Surg Laparosc Endosc Percutan Tech. 2016 Dec;26(6):e132-e136
pubmed: 27846181
Int J Surg. 2016 May;29:118-22
pubmed: 27034118
Asian J Endosc Surg. 2015 Feb;8(1):1-10
pubmed: 25496345
BMJ Open. 2019 Apr 20;9(4):e026271
pubmed: 31005930
J Gastric Cancer. 2019 Mar;19(1):102-110
pubmed: 30944763
Int Surg. 2013 Jul-Sep;98(3):247-53
pubmed: 23971779
Surg Endosc. 2018 Oct;32(10):4344-4350
pubmed: 29785459
Surg Innov. 2017 Apr;24(2):171-182
pubmed: 28164741
Dig Surg. 2012;29(3):261-8
pubmed: 22907557
Eur J Epidemiol. 2010 Sep;25(9):603-5
pubmed: 20652370
Surg Endosc. 2019 Jun;33(6):1828-1836
pubmed: 30284022
CA Cancer J Clin. 2019 Sep;69(5):363-385
pubmed: 31184787
Surg Laparosc Endosc Percutan Tech. 2019 Aug;29(4):297-303
pubmed: 30969195
Surg Endosc. 2018 Feb;32(2):735-742
pubmed: 28726137
Gastric Cancer. 2015 Oct;18(4):868-75
pubmed: 25398519
Ann Surg Oncol. 2015 Aug;22(8):2567-72
pubmed: 25564174
Transl Gastroenterol Hepatol. 2016 May 09;1:38
pubmed: 28138605
J Gastric Cancer. 2018 Jun;18(2):172-181
pubmed: 29984067
J Invest Surg. 2018 Dec;31(6):455-463
pubmed: 28829648
Ann Surg Oncol. 2018 Nov;25(12):3604-3612
pubmed: 30178393
BMC Med Res Methodol. 2019 Aug 5;19(1):170
pubmed: 31382898
Gastric Cancer. 2013 Oct;16(4):602-8
pubmed: 23179368